Investigation of an Alternative Marker for Hypermutability Evaluation in Different Tumors

A growing number of studies have shown immunotherapy to be a promising treatment strategy for several types of cancer. Short tandem repeats (STRs) have been proven to be alternative markers for the evaluation of hypermutability in gastrointestinal (GI) cancers. However, the status of STRs and micros...

Full description

Saved in:

Bibliographic Details
Published in:	Genes 2021-01, Vol.12 (2), p.197
Main Authors:	Chen, Anqi, Zhang, Suhua, Xiong, Lei, Xi, Shihan, Tao, Ruiyang, Chen, Chong, Li, Jixi, Chen, Jinzhong, Li, Chengtao
Format:	Article
Language:	eng
Subjects:	Breast cancer Colorectal cancer Colorectal carcinoma Esophagus FDA approval Gastric cancer hypermutability Immunotherapy Investigations Lung cancer Microsatellite instability microsatellite instability (MSI) Mutation Pancreatic cancer Patients Short tandem repeats short tandem repeats (STRs) Tumors
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	A growing number of studies have shown immunotherapy to be a promising treatment strategy for several types of cancer. Short tandem repeats (STRs) have been proven to be alternative markers for the evaluation of hypermutability in gastrointestinal (GI) cancers. However, the status of STRs and microsatellite instability (MSI) in other tumors have not yet been investigated. To further compare STR and MSI alterations in different tumors, a total of 407 paired DNAs were analyzed from the following eight tumor types: breast cancer (BC), hepatocellular cancer (HCC), pancreatic cancer (PC), colorectal cancer (CRC), gastric cancer (GC), lung cancer (LC), esophageal cancer (EC), and renal cell cancer (RCC). The STR alteration frequencies varied in different tumors as expected. Interestingly, none of the patients possessed MSI-low (MSI-L) or MSI-high (MSI-H), except for the GI patients. The highest STR alteration was detected in EC (77.78%), followed by CRC (69.77%), HCC (63.33%), GC (54.55%), LC (48.00%), RCC (40.91%), BC (36.11%), and PC (25.71%). The potential cutoff for hypermutability was predicted using the published objective response rate (ORR), and the cutoff of LC and HCC was the same as that of GI cancers (26.32%). The cutoffs of 31.58% and 10.53% should be selected for BC and RCC, respectively. In summary, we compared MSI and STR status in eight tumor types, and predicted the potential threshold for hypermutability of BC, HCC, CRC, GC, LC, EC, and RCC.
ISSN:	2073-4425 2073-4425